Hepatocellular carcinoma (HCC) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	surveillance
Linked regimen	`None`

ID	`IND-A1AT-DEFICIENCY-HCC-LUNG-PREVENTION-OBSERVATION`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-HCC`
Sources	`SRC-AASLD-HCC-2023` `SRC-NCCN-BCELL-2025` `SRC-NCCN-NSCLC-2025`

Notes

STUB — alternative-track companion for A1AT / HCC + lung prevention. Required for §15.2 C4 ≥2-tracks invariant. Two-Co-Lead signoff queued.

Used By

Red flag

RF-A1AT-DEFICIENCY-HCC-LUNG-PREVENTION - Alpha-1 antitrypsin (A1AT) deficiency, particularly homozygous PiZZ genotype (severe defi...